These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 2432827)

  • 1. Effect of hydroxyethyl starch (HES) in reducing parasite load in experimental visceral leishmaniasis.
    Jarecki-Black JC; Atkins L; Pratt KM; Pepkowitz SH; Glassman AB
    Ann Clin Lab Sci; 1986; 16(6):450-4. PubMed ID: 2432827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance against Leishmania donovani induced with an aluminum hydroxide vaccine.
    Jarecki-Black JC; Hallman KL; James ER; Glassman AB
    Ann Clin Lab Sci; 1988; 18(1):72-7. PubMed ID: 3355098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithymocyte serum suppression of immunity in mice immunized to Leishmania donovani.
    Runey GL; Jarecki-Black JC; Runey MW; Glassman AB
    Ann Clin Lab Sci; 1990; 20(4):263-7. PubMed ID: 2403241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes.
    Ali N; Afrin F
    J Parasitol; 1997 Feb; 83(1):70-5. PubMed ID: 9057699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis.
    Rachamim N; Jaffe CL
    J Immunol; 1993 Mar; 150(6):2322-31. PubMed ID: 8450215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice.
    Tonui WK; Titus RG
    Am J Trop Med Hyg; 2007 Mar; 76(3):579-84. PubMed ID: 17360887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
    Bhaumik SK; Naskar K; De T
    Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
    Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
    FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection.
    Carter KC; Henriquez FL; Campbell SA; Roberts CW; Nok A; Mullen AB; McFarlane E
    Vaccine; 2007 May; 25(22):4502-9. PubMed ID: 17418459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of BCG-vaccine upon experimental visceral leishmaniasis in hamsters.
    Jarecki-Black JC; Glassman AB; Holbrook TW
    Ann Clin Lab Sci; 1984; 14(6):464-6. PubMed ID: 6508226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyethylstarch administration does not depress reticuloendothelial function or increase mortality from sepsis.
    Shatney CH; Chaudry IH
    Circ Shock; 1984; 13(1):21-6. PubMed ID: 6202435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leishmania donovani: immunization against infection as a function of parasite growth phase.
    Jarecki-Black JC; James ER; Kirshtein JW; Kirshtein JD; Glassman AB
    Am J Trop Med Hyg; 1986 Nov; 35(6):1117-20. PubMed ID: 3789267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis.
    Bhardwaj S; Vasishta RK; Arora SK
    Exp Parasitol; 2009 Jan; 121(1):29-37. PubMed ID: 18983842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
    Tripathi P; Gupta SK; Sinha S; Sundar S; Dube A; Naik S
    Scand J Immunol; 2008 Nov; 68(5):492-501. PubMed ID: 18803606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major.
    Bhaumik S; Basu R; Sen S; Naskar K; Roy S
    Vaccine; 2009 Feb; 27(9):1306-16. PubMed ID: 19162111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serodiagnostic and immunoprophylactic potential of a 78kDa protein of Leishmania donovani of Indian origin.
    Mukherjee M; Bhattacharyya A; Duttagupta S
    Med Sci Monit; 2002 Apr; 8(4):BR117-22. PubMed ID: 11951057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani.
    Gamboa-León R; Paraguai de Souza E; Borja-Cabrera GP; Santos FN; Myashiro LM; Pinheiro RO; Dumonteil E; Palatnik-de-Sousa CB
    Vaccine; 2006 May; 24(22):4863-73. PubMed ID: 16635538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis.
    Tewary P; Jain M; Sahani MH; Saxena S; Madhubala R
    J Infect Dis; 2005 Jun; 191(12):2130-7. PubMed ID: 15898000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.